Breakthrough CAR-T Cancer Treatments Are Boosting Patients’ Quality of Life
WEDNESDAY, April 5, 2023 (HealthDay News) — A therapy that bolsters the immune system may not only help certain cancer patients live longer, but better, a new study finds.The treatment, called chimeric antigen receptor (CAR) T-cell therapy, is used t…
Learn MoreNeoadjuvant, Adjuvant Pembrolizumab Beneficial in Resectable Melanoma
FRIDAY, March 10, 2023 (HealthDay News) — For patients with resectable stage III or IV melanoma, event-free survival is longer for those receiving neoadjuvant and adjuvant pembrolizumab compared with those receiving only adjuvant pembrolizumab, accor…
Learn MoreTiming of Melanoma Immunotherapy Could Be Key to Outcomes: Study
MONDAY, March 6, 2023 (HealthDay News) — A tweak in timing may make an immune-system therapy much more effective for patients undergoing surgery for advanced melanoma, a new clinical trial has found.Researchers showed that giving the therapy — a drug…
Learn MoreTargeted Therapies Seem Beneficial for Immune Checkpoint Inhibitor-Related Myotoxicity
THURSDAY, March 2, 2023 (HealthDay News) — A strategy including identification of severe immune checkpoint inhibitor (ICI)-related myocarditis based on screening combined with active ventilation and treatment seems beneficial for reducing the myotoxi…
Learn MorePD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC
FRIDAY, Jan. 13, 2023 (HealthDay News) — For localized mismatch repair-deficient (dMMR) colorectal cancer (CRC), neoadjuvant programmed death-1 (PD-1) inhibitor treatment is effective, according to a study published online Jan. 11 in the Journal of t…
Learn MoreOral Immunotherapy With Boiled Then Roasted Peanuts Feasible
WEDNESDAY, Jan. 11, 2023 (HealthDay News) — Oral immunotherapy (OIT) using boiled followed by roasted peanuts is feasible and safe for treating children with peanut allergy, according to a study published online Jan. 11 in Clinical & Experimental All…
Learn MoreMelanoma Patients Who Fail Standard Meds May Have Another Option
THURSDAY, Dec. 8, 2022 (HealthDay News) — An experimental therapy that uses the body’s own immune system cells may beat a standard treatment for patients with advanced melanoma, a new clinical trial finds.Researchers found that the therapy doubled th…
Learn MoreThere Are No Useful Monoclonal Antibody Treatments Left Against New COVID Variants
MONDAY, Dec. 5, 2022 (HealthDay News) — The last of six COVID monoclonal antibody treatments has lost its federal authorization because, like the others, it no longer works against the newest Omicron subvariants.This last monoclonal antibody was bebt…
Learn MoreQOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma
MONDAY, Nov. 28, 2022 (HealthDay News) — For patients with high-risk resected melanoma, adjuvant pembrolizumab improves quality of life (QOL) compared with standard of care with ipilimumab or high-dose interferon α 2b (HDI), according to a study publ…
Learn MoreLa FDA aprueba el primer medicamento para retrasar el inicio de la diabetes tipo 1
VIERNES, 18 de noviembre de 2022 (HealthDay News) — El jueves, la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobó el primer fármaco que podría retrasar el desarrollo de la diabetes tipo 1 (DT1).El teplizumab (Tzield) se dirige a la…
Learn More